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We describe a gas-liquid chromatographic (GC) method for determination of oxybuprocaine, and a gas chromatograph-
ic-mass

spectrometric (GC-MS) method for simultaneous determination of four of its nine metabolites in urine. We used an Extrelut#{174} column to simply and rapidly extract oxybuprocaine and its metabolites from urine. For the GC-MS analyses, we monitored the characteristic fragment ions at m/z 353, 395, 369, 411, and 235 for 3-butoxy-4-aminobenzoic acid (metabolite 2, M-2), 3-butoxy-4-acetylaminobenzoic acid (M-3), 3-hydroxy-4-aminobenzoic acid (M-4), 3-hydroxy-4-acetylaminobenzoic acid (M-5)
, and methaqualone (internal standard), respectively. We quantified the glucuronide of M-2 after enzymic treatment. The assay's selectivity and reproducibility (within-day and between-day CVs <8% for all metabolites) make it applicable to determine oxybuprocaine and its metabolites in human urine. Mean 9-h urinary excretion of oxybuprocaine and its five metabolites from four healthy volunteers was 89.2% after a 100-mg oral dose.
Oxybuprocaine, a local anesthetic, is similar in structure to procaine. Its metabolism in humans is extensive, nine metabolites as well as the parent drug being detectable in urine (1).
Further to elucidate the metabolism of oxybuprocaine, we used GC' and CC-MS to measure oxybuprocaine and its five principal metabolites in urine specimens from healthy volunteers who had received 100 mg of oxybuprocaine hydrochloride orally.
We also prepared the samples by passing them through 1-mL Extrelut#{174} columns; this extraction generates no emulsions, and so speeds the procedure and provides a high clean-up efficiency (2-6).
Materials and Methods
Reagents:
Oxybuprocaine (Santen Pharmaceutical Co.
Ltd.) was obtained as the hydrochloride salt. Extrelut#{174} (a wide-pore kieselguhr of grainy structure) was purchased from E. Merck, Darmstadt, F.R.G.; the derivatizing reagent for gas chromatography, N,O-bis(trimethylsilyl)acetamide (BSA) from Tokyo Kasei, Tokyo, Japan; and methaqualone from Eizai Co., Tokyo, Japan. Other reagents and solvents were of AR grade.
Faculty of
The authentic metabolites (1) of oxybuprocaine and pramocaine (7, 8) were prepared in the authors' laboratory.
Instrumentation:
For the CC analyses we used a Shimadzu Model CC-6A chromatograph equipped with a hydrogen flame-ionization detector. The 1 m x 3 mm (i.d.) glass column was packed with 2% OV-101 on Chromosorb WHP (100-120 mesh; Hewlett-Packard, Avondale, PA). The column temperature was programmed from 180 to 220 #{176}C at 10 #{176}C/min, then held at 220 #{176}C. The flow rate of the nitrogen carrier gas was 50 mL/min. The injection and the detection temperatures were both 250 #{176}C. We acquired mass spectra with a Hitachi M-5201 gas chromatograph coupled via ajet separator to a Hitachi M-60 mass spectrometer. The 1 m x 2 mm(i.d.) glass column was also packed with 2% OV-101 on Chromosorb WHP (100-120 mesh). The oven temperature was increased from 160 to 200#{176}C at 10 #{176}C/min, then held at 200 #{176}C. The injection and the interface temperatures were 230 and 260 #{176}C, respectively. The flow rate of the helium carrier gas was 50 mL/min. The accelerating voltage was 3.0 kV; the ionizing current, 100 pA; and the ionizing potential, 20 eV. The magnet was scanned from miz 160 to 430 in 8s, with is allowed for field stabilization between scans. Peak areas were calculated by a computer system, Hitachi 002B Datalizer.
Sample collection: Healthy volunteers were given an oral dose of 100 mg of oxybuprocaine hydrochloride, and urine collected at various intervals up to 9 h after the dose was stored at -20 #{176}C until analyzed.
Pretreatment
of the Extrelut column: We used 1-mL Extrelut columns. For assay of the parent drug, we washed the columns with diethyl ether/isopropanol (85/15 by vol). For the acidic metabolites, we loaded 1.0 mL of 0.1 molJL HC1 onto the columns before applying the samples; after 10 mm, we eluted the acidic solution retained in the columns by washing with saturated sodium chloride solution. We then washed the columns with methanol, followed by diethyl ether/isopropanol (85/15 by vol). We assessed the retention capacity of the Extrelut column for each compound by applying 1 mL of 10, 100, 200, 300, and 400 pg/mL solutions of the four metabolites: 3-butoxy-4-aminobenzoic acid (M-2), 3-butoxy-4-acetylaminobenzoic acid (M-3), 3-hydroxy-4-aminobenzoic acid (M-4), and 3-hydroxy-4-acetylaminobenzoic acid (M-5). For elution we used 6 mL of diethyl ether/isopropanol (85/15 by vol). Recovery of each of the synthetic metabolites was determined as described above, except that we measured absorbance at 292 nm for M-2 and M-4, and at 262 nm for M-3 and M-5.
Urine sample preparation of the parent drug: Adjust 1 mL of urine to pH 10 and apply it to the Extrelut column. After 15 mm, elute the parent drug with 6 mL of diethyl ether/ isopropanol Urine sample preparation for assay of the glucuronide of M-2: To 1 mL of acetate buffer (0.2 mol/L, pH 5.0) and 1 mg of f3-glucuronidase (EC 3.2.1.31; 270 Fishman units) in a 15-mL glass-stoppered tube, add 1 mL of urine diluted 1.5-to fivefold with distilled water, and incubate the mixture at 37 #{176}C for 1 h. After centrifuging (700 x g, 15 mm), apply 1 mL of the supernatant fluid to the column. The hydrolyzed metabolite is measured by the same methods used to prepare the acidic metabolites before enzyme treatment. To determine the amount of the glucuronide of M-2 that is present, subtract the amount of the metabolite before enzyme treatment from the amount obtained after enzyme treatment.
Quantification:
We quantified oxybuprocaine by linear regression of the drug/internal standard peak-height ratio vs concentration (0.1-10 j.tg/mL). Each acidic metabolite was determined by linear regression of each metabolite/ internal standard peak-area ratio vs concentration (0.5-20 pg/mL).
Results and Discussion
Most of the metabolites of oxybuprocaine are phenols, aromatic amines, or carboxylic acids. Because of the mode of isolation of these compounds, in preliminary experiments we examined the effect of pH (range 1-4) on extraction by ethyl acetate of authentic metabolites from aqueous solution. Three metabolites showed maximum recoveries over the pH range 1-3; one metabolite was best extracted at pH 3. Accordingly, we extracted the metabolites from volunteers' urine at pH 3, then studied the extraction of these compounds retained in the Extrelut columns in further detail.
Extraction efficiency for 3-hydroxy-4-aminobenzoic acid is
poorer than for the other compounds. Therefore, we used this as the reference compound in deciding what eluent to use. The highest analytical recoveries were obtained when diethyl ether/isopropanol (85/15) and dichloromethane/isopropanol (85/15) were used as eluents. Recovery after eluting with chioroform/acetonitrile (95/5) or chloroform/methanol (90/10) was only 36 to 38.3%. Guided by these results, we routinely used diethyl ether/isopropanol (85/15) as the column eluent.
The Extrelut columns could retain as much as 400 pg of each acidic metabolite. Even at this high concentration, 6 mL of the eluent eluted 97.5% of the metabolites. Thus 6 mL is a sufficient volume for routine use. Figure 1 shows gas chromatograms of a standard solution ( Figure 1A ) and of extracts of human urine obtained by using Extrelut before ( Figure IB) and after ( Figure 1C) oral administration of oxybuprocaine hydrochloride. Both oxybuprocaine and the internal standard were well resolved (retention times of 8.7 and 6.5 mm, respectively). There were almost no peaks interfering with the drug or the internal standard.
The four acidic metabolites could not be determined described, with use of isothermal temperature, was better than when a temperature program was used. Therefore we used a constant column temperature routinely. Figure 2 shows the mass spectra of methaqualone (the internal standard) and of the triniethylsilyl (TMS) derivatives of the major extractable acid metabolites of oxybuprocaine. Because an acetylammno group as well as a carboxyl and a hydroxy group were easily derivatized by BSA, the mass spectra of the TMS derivatives of M-3 and M-5 show strong molecular ions at mlz 395 and 411, respectively. The ions at miz 353,369, and 235 are also selective and provide the base peaks for the TMS derivatives of M-2 and M-4, and for the internal standard, respectively. Therefore, we performed the analyses by focusing at the characteristic fragment ion of each metabolite as follows: miz 353, M-2; 395, M-3; 369, M-4;  411, M-5; and 235, the internal standard (Figure 3) . The retention times of the TMS derivatives of acidic metabolites (M-2, M-3, M-4, and M-5) were 5.3, 6.0, 3.0, and 3.7 mm,  respectively, when assayed at a column temperature of 200#{176}C, and were identical to those of their standard compounds. In blank human urine these monitoring peaks were distinguishable from background and were completely separated from the background peaks.
The correlation coefficients were better than 0.992 for the parent drug, M-3, and M-5, and 0.990 for M-2 and M-4. The calibration curves were linear for each sample over the concentration range studied here.
Mean (± SD) analytical recoveries of 5 pg each of oxybuprocaine, M-2, M-3, M-4, and M-5 added to 1 mL of a control (drug-free) urine were 93.0 ± 1.2%, 92.2 ± 4.3%, 95.3 ± 2.7%, 81.0 ± 3.4%, and 99.2 ± 1.4%, respectively (n = 3).
The precision of the method was assessed at concentrations of 0.2, 0.5, and 1 pg/mL for oxybuprocaine, and 5 and 10 pg/mL for the acidic metabolites. Within-day (n = 5) and between-day (n = 5) CVs for assay of oxybuprocaine ranged from 1.2 to 1.5% and from 1.6 to 3.7%, respectively. The corresponding data for the metabolites were 1.3 to 7.2% and 4.2 to 7.8%.
The present assays are reproducible and specific enough for use in evaluating the metabolism of oxybuprocaine.
We applied the methods to analyses of human urine after oral administration of 100 mg of oxybuprocaine hydrochloride. Figure 4 shows cumulative urinary excretion (% of dose) of oxybuprocaine and its metabolites. Oxybuprocaine is rapidly hydrolyzed to M-2 (9), which is primarily excreted in urine as the glucuromde. The urinary excretion of the drug's metabolites during 9 h was calculated as approximately 83.4%. Only about 6% of the dose was excreted as unconjugated metabolites in urine.
